{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,20]],"date-time":"2026-09-20T23:04:03Z","timestamp":1789945443240,"version":"4.0.1"},"reference-count":43,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2017,5,1]],"date-time":"2017-05-01T00:00:00Z","timestamp":1493596800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2017,5,1]],"date-time":"2017-05-01T00:00:00Z","timestamp":1493596800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","clinical-lymphoma-myeloma-leukemia.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Lymphoma Myeloma and Leukemia"],"published-print":{"date-parts":[[2017,5]]},"DOI":"10.1016\/j.clml.2017.02.024","type":"journal-article","created":{"date-parts":[[2017,3,7]],"date-time":"2017-03-07T07:19:08Z","timestamp":1488871148000},"page":"243-251","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":32,"title":["Treating Multiple Myeloma Patients With Oral Therapies"],"prefix":"10.1016","volume":"17","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5392-9284","authenticated-orcid":false,"given":"Shaji K.","family":"Kumar","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ravi","family":"Vij","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephen J.","family":"Noga","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Deborah","family":"Berg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lonnie","family":"Brent","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lawrence","family":"Dollar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ajai","family":"Chari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.clml.2017.02.024_bib1","doi-asserted-by":"crossref","first-page":"1046","DOI":"10.1056\/NEJMra1011442","article-title":"Multiple myeloma","volume":"364","author":"Palumbo","year":"2011","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.clml.2017.02.024_bib2","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1038\/nrclinonc.2014.200","article-title":"Current treatment landscape for relapsed and\/or refractory multiple myeloma","volume":"12","author":"Dimopoulos","year":"2015","journal-title":"Nat Rev Clin Oncol"},{"key":"10.1016\/j.clml.2017.02.024_bib3","doi-asserted-by":"crossref","first-page":"1122","DOI":"10.1038\/leu.2013.313","article-title":"Continued improvement in survival in multiple myeloma: changes in early mortality and outcomes in older patients","volume":"28","author":"Kumar","year":"2014","journal-title":"Leukemia"},{"key":"10.1016\/j.clml.2017.02.024_bib4","doi-asserted-by":"crossref","first-page":"906","DOI":"10.1056\/NEJMoa1402551","article-title":"Lenalidomide and dexamethasone in transplant-ineligible patients with myeloma","volume":"371","author":"Benboubker","year":"2014","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.clml.2017.02.024_bib5","doi-asserted-by":"crossref","first-page":"1759","DOI":"10.1056\/NEJMoa1112704","article-title":"Continuous lenalidomide treatment for newly diagnosed multiple myeloma","volume":"366","author":"Palumbo","year":"2012","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.clml.2017.02.024_bib6","doi-asserted-by":"crossref","first-page":"3459","DOI":"10.1200\/JCO.2014.60.2466","article-title":"Continuous therapy versus fixed duration of therapy in patients with newly diagnosed multiple myeloma","volume":"33","author":"Palumbo","year":"2015","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clml.2017.02.024_bib7","article-title":"Financial toxicity of cancer care: it's time to intervene","volume":"108","author":"Zafar","year":"2016","journal-title":"J\u00a0Natl Cancer Inst"},{"key":"10.1016\/j.clml.2017.02.024_bib8","first-page":"2789","article-title":"Development of a conceptual model to illustrate the impact of multiple myeloma and its treatment on health-related quality of life","volume":"23","author":"Baz","year":"2015","journal-title":"Support Care Cancer"},{"key":"10.1016\/j.clml.2017.02.024_bib9","article-title":"Duration of therapy in US patients treated for relapsed\/refractory multiple myeloma (RRMM) in the real-world","volume":"538","author":"Romanus","year":"2016","journal-title":"Haematologica"},{"key":"10.1016\/j.clml.2017.02.024_bib10","doi-asserted-by":"crossref","first-page":"e244","DOI":"10.1016\/j.clml.2015.07.519","article-title":"The current unmet medical needs in the treatment and management of multiple myeloma","volume":"15","author":"Richardson","year":"2015","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"10.1016\/j.clml.2017.02.024_bib11","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1111\/j.1365-2141.2009.07728.x","article-title":"Expanded safety experience with lenalidomide plus dexamethasone in relapsed or refractory multiple myeloma","volume":"146","author":"Chen","year":"2009","journal-title":"Br J Haematol"},{"key":"10.1016\/j.clml.2017.02.024_bib12","doi-asserted-by":"crossref","first-page":"2123","DOI":"10.1056\/NEJMoa070594","article-title":"Lenalidomide plus dexamethasone for relapsed or refractory multiple myeloma","volume":"357","author":"Dimopoulos","year":"2007","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.clml.2017.02.024_bib13","doi-asserted-by":"crossref","first-page":"e257","DOI":"10.1038\/bcj.2014.77","article-title":"Efficacy and safety of long-term treatment with lenalidomide and dexamethasone in patients with relapsed\/refractory multiple myeloma","volume":"4","author":"Dimopoulos","year":"2014","journal-title":"Blood Cancer J"},{"key":"10.1016\/j.clml.2017.02.024_bib14","doi-asserted-by":"crossref","first-page":"1055","DOI":"10.1016\/S1470-2045(13)70380-2","article-title":"Pomalidomide plus low-dose dexamethasone versus high-dose dexamethasone alone for patients with relapsed and refractory multiple myeloma (MM-003): a randomised, open-label, phase 3 trial","volume":"14","author":"San Miguel","year":"2013","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.clml.2017.02.024_bib15","doi-asserted-by":"crossref","first-page":"2561","DOI":"10.1182\/blood-2015-11-682518","article-title":"Randomized multicenter phase 2 study of pomalidomide, cyclophosphamide, and dexamethasone in relapsed refractory myeloma","volume":"127","author":"Baz","year":"2016","journal-title":"Blood"},{"key":"10.1016\/j.clml.2017.02.024_bib16","doi-asserted-by":"crossref","first-page":"825","DOI":"10.1016\/S0140-6736(06)68338-4","article-title":"Oral melphalan and prednisone chemotherapy plus thalidomide compared with melphalan and prednisone alone in elderly patients with multiple myeloma: randomised controlled trial","volume":"367","author":"Palumbo","year":"2006","journal-title":"Lancet"},{"key":"10.1016\/j.clml.2017.02.024_bib17","doi-asserted-by":"crossref","first-page":"4459","DOI":"10.1200\/JCO.2007.12.3463","article-title":"Melphalan, prednisone, and lenalidomide treatment for newly diagnosed myeloma: a report from the GIMEMA\u2014Italian Multiple Myeloma Network","volume":"25","author":"Palumbo","year":"2007","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clml.2017.02.024_bib18","doi-asserted-by":"crossref","first-page":"1826","DOI":"10.1182\/blood-2013-11-538835","article-title":"Pomalidomide alone or in combination with low-dose dexamethasone in relapsed and refractory multiple myeloma: a randomized phase 2 study","volume":"123","author":"Richardson","year":"2014","journal-title":"Blood"},{"key":"10.1016\/j.clml.2017.02.024_bib19","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1182\/blood-2016-02-700872","article-title":"Safety and efficacy of pomalidomide plus low-dose dexamethasone in STRATUS (MM-010): a phase 3b study in refractory multiple myeloma","volume":"128","author":"Dimopoulos","year":"2016","journal-title":"Blood"},{"key":"10.1016\/j.clml.2017.02.024_bib20","doi-asserted-by":"crossref","first-page":"1102","DOI":"10.1182\/blood-2015-08-662627","article-title":"Triplet vs doublet lenalidomide-containing regimens for the treatment of elderly patients with newly diagnosed multiple myeloma","volume":"127","author":"Magarotto","year":"2016","journal-title":"Blood"},{"key":"10.1016\/j.clml.2017.02.024_bib21","doi-asserted-by":"crossref","DOI":"10.1182\/blood.V126.23.25.25","volume":"126","author":"Durie","year":"2015","journal-title":"Blood"},{"key":"10.1016\/j.clml.2017.02.024_bib22","doi-asserted-by":"crossref","first-page":"1621","DOI":"10.1056\/NEJMoa1516282","article-title":"Oral ixazomib, lenalidomide, and dexamethasone for multiple myeloma","volume":"374","author":"Moreau","year":"2016","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.clml.2017.02.024_bib23","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1182\/blood-2010-02-268862","article-title":"Lenalidomide, bortezomib, and dexamethasone combination therapy in patients with newly diagnosed multiple myeloma","volume":"116","author":"Richardson","year":"2010","journal-title":"Blood"},{"key":"10.1016\/j.clml.2017.02.024_bib24","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1056\/NEJMoa1411321","article-title":"Carfilzomib, lenalidomide, and dexamethasone for relapsed multiple myeloma","volume":"372","author":"Stewart","year":"2015","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.clml.2017.02.024_bib27","doi-asserted-by":"crossref","DOI":"10.1182\/blood.V126.23.4226.4226","article-title":"A\u00a0phase II study of panobinostat with lenalidomide and weekly dexamethasone in myeloma","volume":"126","author":"Chari","year":"2015","journal-title":"Blood"},{"key":"10.1016\/j.clml.2017.02.024_bib28","doi-asserted-by":"crossref","first-page":"1319","DOI":"10.1056\/NEJMoa1607751","article-title":"Daratumumab, Lenalidomide, and Dexamethasone for Multiple Myeloma","volume":"375","author":"Dimopoulos","year":"2016","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clml.2017.02.024_bib29","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1056\/NEJMoa1505654","article-title":"Elotuzumab therapy for relapsed or refractory multiple myeloma","volume":"373","author":"Lonial","year":"2015","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.clml.2017.02.024_bib31","doi-asserted-by":"crossref","first-page":"2133","DOI":"10.1056\/NEJMoa070596","article-title":"Lenalidomide plus dexamethasone for relapsed multiple myeloma in North America","volume":"357","author":"Weber","year":"2007","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.clml.2017.02.024_bib37","doi-asserted-by":"crossref","first-page":"806","DOI":"10.1002\/ajh.24416","article-title":"An international, multicenter, prospective, observational study of neutropenia in patients being treated with lenalidomide\u00a0+ dexamethasone for relapsed or relapsed\/refractory multiple myeloma (RR-MM)","volume":"91","author":"Leleu","year":"2016","journal-title":"Am J Hematol"},{"key":"10.1016\/j.clml.2017.02.024_bib38","doi-asserted-by":"crossref","first-page":"621958","DOI":"10.1155\/2012\/621958","article-title":"Practical approaches to the use of lenalidomide in multiple myeloma: a Canadian consensus","volume":"2012","author":"Reece","year":"2012","journal-title":"Adv Hematol"},{"key":"10.1016\/j.clml.2017.02.024_bib39","doi-asserted-by":"crossref","first-page":"E202","DOI":"10.1002\/ajh.24118","article-title":"The characterization of adrenal insufficiency and identification of its risk factors in patients with plasma cell dyscrasias","volume":"90","author":"Tremblay","year":"2015","journal-title":"Am J Hematol"},{"key":"10.1016\/j.clml.2017.02.024_bib41","doi-asserted-by":"crossref","first-page":"2467","DOI":"10.1182\/blood-2014-06-583302","article-title":"Lenalidomide-induced diarrhea in patients with myeloma is caused by bile acid malabsorption that responds to treatment","volume":"124","author":"Pawlyn","year":"2014","journal-title":"Blood"},{"key":"10.1016\/j.clml.2017.02.024_bib42","doi-asserted-by":"crossref","first-page":"414","DOI":"10.1038\/sj.leu.2405062","article-title":"Prevention of thalidomide- and lenalidomide-associated thrombosis in myeloma","volume":"22","author":"Palumbo","year":"2008","journal-title":"Leukemia"},{"key":"10.1016\/j.clml.2017.02.024_bib43","doi-asserted-by":"crossref","first-page":"2510","DOI":"10.3109\/10428194.2016.1151507","article-title":"Outcomes and management of lenalidomide-associated rash in patients with multiple myeloma","volume":"57","author":"Barley","year":"2016","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.clml.2017.02.024_bib44","doi-asserted-by":"crossref","first-page":"1047","DOI":"10.1182\/blood-2014-01-548941","article-title":"Phase 1 study of weekly dosing with the investigational oral proteasome inhibitor ixazomib in relapsed\/refractory multiple myeloma","volume":"124","author":"Kumar","year":"2014","journal-title":"Blood"},{"key":"10.1016\/j.clml.2017.02.024_bib47","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1188\/10.CJON.447-453","article-title":"Perceptions and experiences of patients receiving oral chemotherapy","volume":"14","author":"Simchowitz","year":"2010","journal-title":"Clin J Oncol Nurs"},{"key":"10.1016\/j.clml.2017.02.024_bib48","unstructured":"Center for Health Transformation. The 21st Century Intelligent Pharmacy Project: the importance of medication adherence. 2010. Available at: http:\/\/adhereforhealth.org\/wp-content\/uploads\/pdf\/The21stCenturyIntelligentPharmacyProject_MedicationAdherence_Mirixa_2010.pdf."},{"key":"10.1016\/j.clml.2017.02.024_bib49","first-page":"7","article-title":"Adherence, persistence, and treatment fatigue in multiple myeloma","volume":"7","author":"Kurtin","year":"2016","journal-title":"J\u00a0Adv Pract Oncol"},{"key":"10.1016\/j.clml.2017.02.024_bib50","article-title":"Do patients on oral chemotherapy have sufficient knowledge for optimal adherence? A mixed methods study","volume":"26","author":"Arber","year":"2017","journal-title":"Eur J Cancer Care (Engl)"},{"key":"10.1016\/j.clml.2017.02.024_bib51","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1188\/03.CJON.S6.21-24","article-title":"Patient education: the cornerstone of successful oral chemotherapy treatment","volume":"7","author":"Hartigan","year":"2003","journal-title":"Clin J Oncol Nurs"},{"key":"10.1016\/j.clml.2017.02.024_bib52","doi-asserted-by":"crossref","first-page":"610","DOI":"10.1016\/j.ctrv.2012.12.014","article-title":"Determinants and associated factors influencing medication adherence and persistence to oral anticancer drugs: a systematic review","volume":"39","author":"Verbrugghe","year":"2013","journal-title":"Cancer Treat Rev"},{"key":"10.1016\/j.clml.2017.02.024_bib53","doi-asserted-by":"crossref","first-page":"980","DOI":"10.1200\/JCO.2015.64.6620","article-title":"Financial insolvency as a risk factor for early mortality among patients with cancer","volume":"34","author":"Ramsey","year":"2016","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clml.2017.02.024_bib54","first-page":"19","article-title":"Economic and clinical impact of multiple myeloma to managed care","volume":"14","author":"Cook","year":"2008","journal-title":"J\u00a0Manag Care Pharm"}],"container-title":["Clinical Lymphoma Myeloma and Leukemia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2152265016309569?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2152265016309569?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T00:28:38Z","timestamp":1761870518000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2152265016309569"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,5]]},"references-count":43,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2017,5]]}},"alternative-id":["S2152265016309569"],"URL":"https:\/\/doi.org\/10.1016\/j.clml.2017.02.024","relation":{},"ISSN":["2152-2650"],"issn-type":[{"value":"2152-2650","type":"print"}],"subject":[],"published":{"date-parts":[[2017,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Treating Multiple Myeloma Patients With Oral Therapies","name":"articletitle","label":"Article Title"},{"value":"Clinical Lymphoma Myeloma and Leukemia","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clml.2017.02.024","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2017 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}